Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Make New NAMs, Keep the Old: Advancing Physiological Relevance of Existing and Next-Generation NAMs Through Integrated Metabolism
  • Schedule
    Notes
  • Room 302‚ Convention Center
    Set Timezone


Chair: Kenzie Pereira, Applied Research Associates
Co-Chair: Amanda Jurgelewicz, UL Research Institutes' Chemical Insights

Primary Endorser: In Vitro and Alternative Methods Specialty Section


Endorser(s): Women in Toxicology Special Interest Group


Endorser(s): Molecular and Systems Biology Specialty Section


The 21st century has seen a rapid transition from traditional in vivo testing toward the development and implementation of human-relevant new approach methodologies (NAMs), including in vitro, ex vivo, and in silico systems. This transition has been accelerated by increased funding and technological innovation, creating new opportunities to advance chemical hazard assessment. Despite this progress, the majority of in vitro NAMs lack the metabolic complexity of living systems, which can transform parent compounds into metabolites with distinct and sometimes increased bioactive profiles, thus limiting confidence in their ability to predict in vivo responses and constraining their regulatory application. In vivo, the biotransformation of compounds is driven largely by the liver (hepatic system), where Phase I and Phase II metabolic enzymes can modify compound structure and generate metabolites with altered potency, toxicity, and target specificity. Because many in vitro NAMs possess limited or no metabolic capability, they largely assess only parent compound bioactivity, increasing the risk of under- or overestimating human health hazards. Addressing this gap is essential to improving the physiological relevance, predictive performance, and regulatory confidence of NAM-based assessments. This session addresses this unmet need by showcasing innovative strategies for integrating metabolic competency into both existing and next-generation NAMs, while demonstrating the importance of metabolism through comparisons of parent compound and metabolite bioactivity. The first three presentations highlight the integration of exogenous metabolism using animal-derived hepatic S9 fractions across diverse NAM platforms and biological systems, including high-throughput phenotypic profiling and transcriptomics for estrogenic toxicity, stem cell-based mechanistic genotoxicity assays, and human stem cell-derived developmental neurotoxicity models. Animal-derived hepatic S9 fractions are widely used because they provide a well-characterized, reproducible, and less variable source of exogenous Phase I/II metabolic activity and often generate metabolites comparable to those observed in humans. However, interspecies differences in metabolic profiles have been reported, highlighting the utility and limitations of exogenous metabolic activation systems and underscoring the need for more human-relevant approaches with endogenous metabolic capacity.The fourth presenter addresses this need through an advanced microphysiological system incorporating co-cultures of human hepatocytes and thyrocytes to model dynamic liver-thyroid interactions. In contrast to pre-metabolized compounds (S9-mediated biotransformation), microphysiological systems can capture time-dependent Phase I and Phase II metabolism, intercellular signaling, and tissue-specific responses in real time, thereby improving the human relevance and physiological fidelity of in vitro toxicity testing. Collectively, the presentations in this session provide a comprehensive framework for increasing the physiological relevance of in vitro NAMs through integrated metabolic competence across diverse test systems.The speakers within this session represent a diverse and multidisciplinary group spanning federal government, academia, and industry, including both pharmaceutical and agrochemical sectors. The panel brings together expertise across multiple areas of toxicology, including endocrine disruption (estrogen and thyroid systems), mechanistic genotoxicity, and developmental neurotoxicity. Further, speakers represent a range of career stages, from early-career researchers to senior scientific leadership, providing both emerging and established perspectives. Together, the speakers in this session offer complementary expertise and a broad range of scientific approaches, ensuring a balanced and integrative discussion of how metabolic competency can be incorporated into NAMs.

Session and Activity Type
Presentations